SPOTLIGHT: Cougar Biotech raises $87M

Los Angeles-based Cougar Biotechnology announced that it has raised $87 million in a private placement. Much of that money will be spent on developing Cougar's drug candidates, including CB7630 (abiraterone acetate), CB3304 (noscapine) and CB1089 (seocalcitol). Cougar specializes in oncology drugs. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.